摘要
Topotecan乃topoisomerase I抑制劑，已被證明對paclitaxel和platinum治療失敗後之卵巢癌，是第二線有效治療藥物。Topotecan有靜脈注射和口服使用兩種方式，口服使用在臨床上不受食物影響。與注射topotecan相同，影響口服topotecan使用劑量最大關鍵乃骨髓毒性，但因口服topotecan使用上較方便，尖峰濃度低，和血液毒性減少，因此，口服topotecan似乎為一有效、有耐受性、和方便之治療卵巢癌復發的第二線藥物。
並列摘要
Topotecan, a topoisomerase 1 inhibitor, is an approved drug used for the second-line treatment of ovarian cancer patients whose tumor have become refractory to conventional first-line therapy, e.g. paclitaxel plus platinum-based doublet chemotherapy. Topotecan could be used either by intravenous or oral route. Oral topotecan should not matter clinically whether patients take the drug with or without food. As with intravenous topotecan, myelo suppression is the dose-limiting toxicity of oral topotecan. However, the oral formulation of topotecan was chosen for use because of its potential convenience, lower peak topotecan concentration, and decreased hematologic toxicity compared with the intravenous formulation. Therefore, oral topotecan seems to have active, tolerable, and convenient formulation of an established agent for the second-line treatment of recurrent ovarian cancer.
延伸閱讀
- 李耀泰、陳福民、郭宗正（2011）。Topotecan治療子宮頸癌的檢視。中華民國婦癌醫學雜誌，(2011年1)，15-24。https://doi.org/10.7010/JGO.201104.0015
- 李耀泰、陳福民、郭宗正（2022）。Niraparib治療卵巢癌的檢視。婦癌醫學期刊，(55)，1-5。https://www.airitilibrary.com/Article/Detail?DocID=P20150521002-202204-202204290007-202204290007-1-5
- 李耀泰、陳福民、郭宗正（2020）。Rucaparib治療復發性卵巢癌的檢視。婦癌醫學期刊，(51)，22-26。https://www.airitilibrary.com/Article/Detail?DocID=P20150521002-202004-202004210005-202004210005-22-26
- 李耀泰、陳福民、侯廣瓊、鄭文雄、郭宗正（2008）。Docetaxel治療卵巢癌之檢視。中華民國婦癌醫學雜誌，(2008年1)，7-13。https://doi.org/10.7010/JGO.200804.0007
- 李耀泰、陳福民、鄭文雄、郭宗正（2007）。Oral Chemotherapeutic Agents for Ovarian Cancer。中華民國婦癌醫學雜誌，(2007年1)，33-39。https://doi.org/10.7010/JGO.200704.0033